---
title: "Amantadine - Postencephalitic Parkinsonism"
sidebar: mydoc_sidebar
permalink: db00915-mesh-d010301-1.html
toc: false 
---


Path ID: `DB00915_MESH_D010301_1`
{% include image.html url="images/db00915-mesh-d010301-1.png" file="db00915-mesh-d010301-1.png" alt="db00915-mesh-d010301-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D000547 | Amantadine | Drug |
| UniProt:P14416 | D(2) dopamine receptor | Protein |
| MESH:D004298 | Dopamine | ChemicalSubstance |
| GO:0061527 | Dopamine secretion, neurotransmission | BiologicalProcess |
| UBERON:0002038 | Substantia nigra | GrossAnatomicalStructure |
| MESH:D010301 | Postencephalitic parkinsonism | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Amantadine | INCREASES ACTIVITY OF | D(2) Dopamine Receptor |
| D(2) Dopamine Receptor | POSITIVELY CORRELATED WITH | Dopamine |
| Dopamine | POSITIVELY CORRELATED WITH | Dopamine Secretion, Neurotransmission |
| Dopamine Secretion, Neurotransmission | OCCURS IN | Substantia Nigra |
| Substantia Nigra | DISRUPTED BY | Postencephalitic Parkinsonism |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00915#BE0000756](https://go.drugbank.com/drugs/DB00915#BE0000756)
  - [https://en.wikipedia.org/wiki/Postencephalitic_parkinsonism](https://en.wikipedia.org/wiki/Postencephalitic_parkinsonism)
